Common Names

  • Chromium III
  • Chromium picolinate
  • Niacin-bound chromium
  • Chromium chloride

For Patients & Caregivers

Chromium may help to regulate blood glucose in some people, but the long-term effects are unknown. There is no clear evidence to show that chromium supplementation is effective for improving glucose metabolism, losing weight, or building muscle mass.

Chromium is an element required by the body in very small amounts (0.025 mg a day). Adequate amounts are usually obtained in the diet from foods such as American cheese, meat, fish, fruits, and whole grains. Based on laboratory experiments, scientists think that chromium is involved in maintaining adequate levels of glucose, fats, and insulin activity in the body. Chromium may interact with insulin receptors and enhance the effects of insulin on cells, including improved glucose uptake. In theory, this could help patients with type 2 diabetes.

Chromium is sometimes combined with GTF (Glucose Tolerance Factor) in over-the-counter products. GTF is a yeast extract that helps with glucose metabolism in laboratory studies, but this effect has not been confirmed in humans.

  • To treat diabetes
    Clinical trials produced conflicting results regarding chromium’s ability to lower blood glucose, cholesterol, and triglycerides.
  • To improve muscle mass
    Clinical trials do not support this use.
  • To improve weight loss
    Clinical trials do not support this use.
  • To treat depression
    Preliminary studies suggest some benefits with chromium supplementation for some types of depression and mood symptoms. More studies are needed.
  • You have liver or kidney problems: There have been some case reports of liver and kidney toxicities with chromium supplements.
  • You are taking sulfonylureas or insulin: Chromium can lower your blood sugar even more.

In rare cases, liver toxicity has occurred.

Case reports

  • Kidney failure: In two patients who took chromium supplements to enhance weight loss.
  • Red skin lesions: Accompanied with fever, swelling, and high white blood cell counts.
  • Destruction of skeletal muscle: In one patient while taking chromium picolinate in addition to other dietary supplements. Therefore, whether chromium caused this condition is not clear.
  • Low blood sugar: In a 29-year-old man with type 2 diabetes who took chromium supplements in addition to insulin.
Back to top

For Healthcare Professionals

Chromium is a trace element that is necessary for glucose, insulin, and lipid metabolism in humans (1) (9). It is marketed as a dietary supplement for diabetes, weight loss, and to improve muscle mass. Trivalent chromium from yeast extract is sometimes referred to as glucose tolerance factor (GTF) in over-the-counter products.

Although most people consume adequate amounts through diet, chromium deficiency has been implicated in the development of diabetes (25). In vitro studies suggest that chromium produces beneficial modulatory effects under hyperglycemic conditions (26). Animal models also suggest antidiabetic (27) (28), antidepressant (29) (30) (31), and anxiolytic (32) properties.

In human studies, chromium supplementation with biotin may help to improve glycemic control in type 2 diabetes (T2D) (4) (5) (6). In a trial of patients with poorly controlled T2D, chromium supplementation had beneficial effects on glycemic control without affecting lipid profiles (33). Another study showed that chromium picolinate may increase satiety (15). However, many clinical studies failed to demonstrate a beneficial effect of chromium on glucose metabolism, weight loss, or muscle mass improvement (3) (7) (8) (9) (10) (11) (12) (13) (14).

Due to lack of clinical evidence, the FDA stated that chromium picolinate did not reduce the risk of insulin resistance or type-2 diabetes (16). More recently, the debate has continued, with one meta-analysis determining that overall, chromium monosupplementation significantly improved glycemic control, increased HDL-C levels, and reduced triglycerides (34), while another meta-analysis determined that chromium picolinate did not significantly affect A1C, and had no effect on fasting plasma glucose (35). Other clinicians posit that the mixed and modest effect sizes seen with chromium supplementation may reflect a greater glucoregulatory effect in complex patients with comorbid diabetes, depression, and binge eating (36). A large population study determined that those who consumed chromium-containing supplements had a reduced risk of T2D compared with those who did not, and warranted further study given the magnitude of exposure (37).

In other studies, chromium picolinate supplementation improved cerebral and memory function in elderly patients with early memory decline (17), produced antidepressant effects in patients with atypical depression (38), and improved mood symptoms in patients with premenstrual dysphoric disorder (39).

Chromium is poorly absorbed following oral administration, but salt forms such as chromium picolinate, niacin-bound chromium, and chromium chloride, appear to have better bioavailability. Other novel chromium compounds also have improved bioavailability (40) (41). Adverse effects are rare but can include renal failure (18) (19), rhabdomyolysis (20), liver damage (21), and dermatitis (22).

Liver, American cheese, broccoli, brewer’s yeast, wheat germ, meat, eggs, chicken, fish, fruits, whole grains, brown sugar, alfalfa, and animal fats (1) (25)

  • Diabetes
  • Depression
  • Strength and stamina
  • Weight loss

Chromium is an essential trace element involved with glucose and lipid metabolism, circulating insulin levels, and the peripheral activity of insulin (1). In vitro and in vivo studies suggest that chromium potentiates the activity of insulin (23) (42). This is thought to occur via enhanced intracellular tyrosine kinase activity that results from an interaction between chromium, low molecular weight chromium-binding substance, and activated cell surface insulin receptors (2).

In animal models of diabetes, chromium recovered beta cell functioning and alleviated macroangiopathy (27). It also augmented the insulin signaling pathway, dulled negative-regulators of insulin signaling, enhanced adenosine monophosphate-activated protein kinase (AMPK) activity to increase cellular glucose uptake, and attenuated oxidative stress (42). Chromium may also modulate peroxisome proliferator-activated receptor-gamma (PPAR-gamma), insulin receptor substrate (IRS-1), and nuclear factor-kappaB (NF-κB) proteins (28). Antidepressant effects occur via modified brain 5-hydroxytryptamine receptor (5-HT) function and increased serotonergic and noradrenergic functioning (30) (31). Additional mechanisms for antidepressant and anxiolytic effects include the lowering of plasma corticosterone levels via reversal of hypothalamic–pituitary–adrenal axis (HPA) axis overactivity (32). In humans, suggested antidepressant mechanisms include 5HT2A downregulation and increased insulin sensitivity (38).

Patients with liver or renal insufficiency may have increased susceptibility to adverse effects (24).

Rare: Hepatic toxicity (21)

Case reports
Renal failure: In a 33-year-old white woman who also presented with weight loss, anemia, thrombocytopenia, hemolysis, and liver dysfunction after chronic high doses of chromium picolinate to enhance weight loss (18) ; and in a 49-year-old female nurse who took chromium picolinate 600 mcg daily for 6 weeks for weight reduction (19).
Acute generalized exanthematous pustulosis: Characterized by erythematous lesions, fever, edema, leukocytosis, and eosinophilia (22).
Rhabdomyolysis: In a 24-year old patient taking chromium picolinate in addition to other dietary supplements (20).
Hypoglycemia: In a 29-year-old man with T2D after ingesting oral chromium 1000 mcg daily in addition to taking insulin (43).

Sulfonylureas/insulin: Chromium can have additive hypoglycemic effects (43).

  1. Porter DJ, Raymond LW, Anastasio GD. Chromium: friend or foe? Arch Fam Med 1999;8:386-90.

  2. Vincent JB. The biochemistry of chromium. J Nutr 2000;130:715-8.

  3. Christopher H. Bailey. Improved Meta-Analytic Methods Show No Effect of Chromium Supplements on Fasting Glucose. Biological Trace Element Research, 2013; 157 (1):1-8.

  4. Albarracin CA, Fuqua BC, Evans JL, Goldfine ID. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev. Jan-Feb 2008;24(1):41-51.

  5. Grant KE, et al. Chromium and exercise training: Effect on obese women. Med Sci Sports Exercise 1997;29:992-8.

  6. Ali A, Ma Y, Reynolds J, et al. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr Pract. 2011 Jan-Feb;17(1):16-25.

  7. Iqbal N, Cardillo S, Volger S, et al. Chromium picolinate does not improve key features of metabolic syndrome in obese nondiabetic adults. Metab Syndr Relat Disord. 2009 Apr;7(2):143-50.

  8. Anton SD, Morrison CD, Cefalu WT, et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technol Ther. Oct 2008;10(5):405-412.

  9. Letter from FDA. Chromium picolinate and Insulin resistance. Accessed December 8, 2009.

  10. Krikorian R, Eliassen JC, Boespflug EL, et al. Improved cognitive-cerebral function in older adults with chromium supplementation. Nutr Neurosci. 2010 Jun;13(3):116-22.

  11. Cerulli J, et al. Chromium picolinate toxicity. Ann Pharmacother 1998; 32:428-31.

  12. Wasser WG, Feldman NS, D’Agati VD. Chronic renal failure after ingestion of over-the-counter chromium picolinate. Ann Int Med 1997;126:410.

  13. Martin WR, Fuller RE. Suspected chromium picolinate-induced rhabdomyolysis. Pharmacotherapy 1998;18:860-2.

  14. Young PC, et al. Acute generalized exanthematous pustulosis induced by chromium picolinate. J Am Acad Dermatol 1999;41:820-3.

  15. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington: National Academy Press; 2001.

  16. Mlyniec K, Davies CL, de Aguero Sanchez IG, et al. Essential elements in depression and anxiety. Part I. Pharmacol Rep. Aug 2014;66(4):534-544.

  17. Iovieno N, Dalton ED, Fava M, et al. Second-tier natural antidepressants: review and critique. J Affect Disord. May 2011;130(3):343-357.

  18. Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther. Jun 2014;39(3):292-306.

  19. Brownley KA, Boettiger CA, Young L, et al. Dietary chromium supplementation for targeted treatment of diabetes patients with comorbid depression and binge eating. Med Hypotheses. Jul 2015;85(1):45-48.

  20. McIver DJ, Grizales AM, Brownstein JS. Risk of Type 2 Diabetes Is Lower in US Adults Taking Chromium-Containing Supplements. Dec 2015;145(12):2675-2682.

  21. Davidson JR, Abraham K, Connor KM, et al. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry. Feb 1 2003;53(3):261-264.

  22. Brownley KA, Girdler SS, Stout AL, et al. Chromium supplementation for menstrual cycle-related mood symptoms. J Diet Suppl. Dec 2013;10(4):345-356.

  23. Ulas M, Orhan C, Tuzcu M, et al. Anti-diabetic potential of chromium histidinate in diabetic retinopathy rats. BMC Complement Altern Med. 2015;15:16.

  24. Peng M, Yang X. Controlling diabetes by chromium complexes: The role of the ligands. J Inorg Biochem. May 2015;146:97-103.

  25. Hua Y, Clark S, Ren J, et al. Molecular mechanisms of chromium in alleviating insulin resistance. J Nutr Biochem. Apr 2012;23(4):313-319.

  26. Bunner SP, McGinnis R. Chromium-induced hypoglycemia. Psychosomatics. May-Jun 1998;39(3):298-299.

Back to top
Back to top
Email your questions and comments to

Last Updated